TipRanks
Advertisement
Advertisement

SBMFF Stock Latest News

Sino Biopharm’s IL-4R Antibody for Atopic Dermatitis Clears Key Regulatory Hurdle in China
Company AnnouncementsSino Biopharm’s IL-4R Antibody for Atopic Dermatitis Clears Key Regulatory Hurdle in China
4d ago
Sino Biopharmaceutical’s HER2-Low Breast Cancer ADC Wins China NDA Acceptance
PremiumCompany Announcements
Sino Biopharmaceutical’s HER2-Low Breast Cancer ADC Wins China NDA Acceptance
4d ago
Sino Biopharm Raises CT Tianqing Stake to 65% in RMB4.48 Billion Deal
PremiumCompany Announcements
Sino Biopharm Raises CT Tianqing Stake to 65% in RMB4.48 Billion Deal
8d ago
Sino Biopharm Showcases Promising Oral STAT6 Degrader Data at ERS 2026
PremiumCompany Announcements
Sino Biopharm Showcases Promising Oral STAT6 Degrader Data at ERS 2026
11d ago
Sino Biopharm’s TQC3721 COPD Inhaler Shows Strong Phase I Data
PremiumCompany Announcements
Sino Biopharm’s TQC3721 COPD Inhaler Shows Strong Phase I Data
12d ago
Sino Biopharm Wins FDA Green Light for Novel GPC3-Targeting Cancer ADC Trial
PremiumCompany AnnouncementsSino Biopharm Wins FDA Green Light for Novel GPC3-Targeting Cancer ADC Trial
16d ago
Sino Biopharm Strikes Exclusive HER2 ADC Deal With Cipla to Boost Emerging-Market Reach
Premium
Company Announcements
Sino Biopharm Strikes Exclusive HER2 ADC Deal With Cipla to Boost Emerging-Market Reach
19d ago
Sino Biopharm’s Kylo-11 Shows Year-Long Lp(a) Cut in Phase I Trial
Premium
Company Announcements
Sino Biopharm’s Kylo-11 Shows Year-Long Lp(a) Cut in Phase I Trial
20d ago
Sino Biopharm Wins China, U.S. Green Lights for Next-Gen Nectin-4 ADC LM-364
PremiumCompany Announcements
Sino Biopharm Wins China, U.S. Green Lights for Next-Gen Nectin-4 ADC LM-364
22d ago
Sino Biopharm Wins Trial Nod for Novel Obesity Antibody TQF6422
PremiumCompany Announcements
Sino Biopharm Wins Trial Nod for Novel Obesity Antibody TQF6422
29d ago
Sino Biopharmaceutical: Strong Profit Beat, Rapid Innovative Franchise Expansion; Buy Rating Reiterated with Unchanged $7.8 Price Target
PremiumRatings
Sino Biopharmaceutical: Strong Profit Beat, Rapid Innovative Franchise Expansion; Buy Rating Reiterated with Unchanged $7.8 Price Target
1M ago
Sino Biopharmaceutical Interim Results Highlight Surge in Innovative Drug and Out-Licensing Revenue
PremiumCompany Announcements
Sino Biopharmaceutical Interim Results Highlight Surge in Innovative Drug and Out-Licensing Revenue
1M ago
Sino Biopharmaceutical Declares 2026 Interim Dividend of HKD 0.07 Per Share
PremiumCompany AnnouncementsSino Biopharmaceutical Declares 2026 Interim Dividend of HKD 0.07 Per Share
1M ago
Sino Biopharm Wins NMPA Approval for New First-Line Lung Cancer Regimen
Premium
Company Announcements
Sino Biopharm Wins NMPA Approval for New First-Line Lung Cancer Regimen
1M ago
Sino Biopharm Wins Approval for Next-Generation Flurbiprofen Pain Patch
Premium
Company Announcements
Sino Biopharm Wins Approval for Next-Generation Flurbiprofen Pain Patch
1M ago
Sino Biopharmaceutical Sets Board Meeting to Approve Interim Results and Consider Dividend
PremiumCompany Announcements
Sino Biopharmaceutical Sets Board Meeting to Approve Interim Results and Consider Dividend
1M ago
Sino Biopharm Wins China CDE Acceptance for Novel Leukemia Drug TQB3909
PremiumCompany Announcements
Sino Biopharm Wins China CDE Acceptance for Novel Leukemia Drug TQB3909
2M ago
Sino Biopharm’s HER2 bispecific ADC TQB2102 gains third breakthrough tag in China
PremiumCompany Announcements
Sino Biopharm’s HER2 bispecific ADC TQB2102 gains third breakthrough tag in China
2M ago
Sino Biopharmaceutical to Showcase 21 Oncology Studies at 2026 CSCO Meeting
PremiumCompany Announcements
Sino Biopharmaceutical to Showcase 21 Oncology Studies at 2026 CSCO Meeting
2M ago
Sino Biopharmaceutical Forms Indonesia Joint Venture With Tempo Scan
PremiumCompany AnnouncementsSino Biopharmaceutical Forms Indonesia Joint Venture With Tempo Scan
2M ago
Sino Biopharm Wins NMPA Nod for Innovative Hepatitis B Drug Trial
Premium
Company Announcements
Sino Biopharm Wins NMPA Nod for Innovative Hepatitis B Drug Trial
2M ago
Sino Biopharmaceutical Wins Breakthrough Status for AI-Designed Neuropathic Pain Drug TRD205
Premium
Company Announcements
Sino Biopharmaceutical Wins Breakthrough Status for AI-Designed Neuropathic Pain Drug TRD205
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >